We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Optimal Therapy Discovered for Vocal Cord Cancer

By MedImaging International staff writers
Posted on 09 May 2017
Print article
The results of a major study comparing radiotherapy treatment options for vocal cord cancer indicate new optimal radiation treatment therapies for the disease.

Current treatment options for Early-Stage Glottic Cancer (ESGC) include both Conventionally-Fractionated Radiotherapy (CFX), and HypoFractionated Radiotherapy (HFX).

The study was published in the April 26, 2017, issue of the Journal of the National Cancer Institute by researchers from the Yale Cancer Center. The researchers used clinical data from a large national database in the US, from the period 2004 to 2013, for the study. The study group consisted of 10,212 patients diagnosed with stage 1 or 2 glottic cancer. Most of the patients, 6,182 (60.5%) in number, were treated with CFX. The rest, 4030 patients (39.5%) were treated with HFX.

The results of the study show that for patients treated with definitive radiotherapy for ESGC cancer, HFX radiotherapy treatment resulted in improved survival compared to CFX radiotherapy treatment. This was especially the case for patients with stage 2 ESGC.

Lead author of the study, Assistant Professor Zain A. Husain, MD, said, “This is an important finding as the optimal fractionation for early stage glottic cancer has long been an area of controversy. These results strongly support hypofractionation as a preferred treatment approach. It is also reassuring to that our results show the utilization of hypofractionation has been increasing considerably.”

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
MRI System
uMR 588
New
Ultrasound System
Acclarix AX9
Under Table Shield
3 Section Double Pivot Under Table Shield

Print article

Channels

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.